|Videos|December 14, 2022
Interview with Syngene at CPHI in Frankfurt, Germany
Author(s)Syngene
KEY LEARNING OBJECTIVES
- Syngene is an end-to-end CRO/CDMO which offers standalone as well as integrated services for small molecules and biologics
- We not only have capabilities but also capacity to fulfil commercial manufacturing requirements
- We can be a innovation partner for niche areas as well as small biotech/pharma companies
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
Trending on Pharmaceutical Technology
1
Lilly Invests $3.5B in Pennsylvania Injectable Medicine Facility
2
Navigating the Complex Risks of Accelerated Pharmaceutical Launches
3
Securing Radiopharma and GLP-1 Supply Chains Through 2026 M&A
4
Repertoire Immune Medicines and Lilly Collaborate on Treatments for Autoimmune Diseases
5